Sphingotec LLC

sphingotec GmbH aims to develop diagnostic methods for prediction, prevention, intervention strategies and early treatment of diseases in the fields of cancer, cardiovascular diseases and kidney function. In order to realize this mission we provide biomarkers indicating susceptibility for a specific disease which enables the monitoring of prevention and intervention strategies. The company was established in 2002 by Dr. Andreas Bergmann who is one of the founders and managers of B.R.A.H.M.S. Aktiengesellschaft where, in addition to several other biomarkers, the sepsis marker Procalcitonin (B.R.A.H.M.S PCT®) was developed in his role as Chief Research Officer. This biomarker Procalcitonin created a new diagnostic standard of care supporting patient management in sepsis. sphingotec is located in Hennigsdorf, northwest of Berlin, Germany, with its facilities in the Technology Campus one of the largest industrial parks in Berlin and Brandenburg with several companies of the biotechnology branch located there.